Understanding the Clinical Scenario
The client is receiving vinblastine, a vinca alkaloid classified as a
vesicant. Vesicants are agents that can cause severe tissue necrosis, blistering, and ulceration if they leak outside the vein into surrounding tissue. The client’s report of burning at the site, visible swelling, and absence of blood return strongly suggests
extravasation—the unintended leakage of a vesicant into perivascular or subcutaneous tissue
[1][2]. This is an oncologic emergency requiring immediate, sequenced intervention to minimize tissue damage.
The correct sequence is: stop the injection first, then aspirate residual drug through the catheter while it remains in place, then remove the catheter, and finally administer hyaluronidase with warm compresses as ordered. This order reflects the principle of halting further injury before attempting drug recovery, and only then removing the access device.
Step-by-Step Rationale for the Sequence
| Step | Action | Rationale |
|---|
| 1 | Stop the injection | Immediately halts further instillation of the vesicant into tissue, limiting the total volume of drug that can cause injury. This is the universal first action in any suspected extravasation [1][2]. |
| 2 | Aspirate residual drug through the catheter | The catheter tip may still lie within or near the extravasation pocket. Gentle aspiration can remove some of the leaked drug, reducing the local drug burden before the catheter is withdrawn [1][3]. |
| 3 | Remove the catheter | Only after aspiration is the catheter removed. Removing it first would eliminate the only route for recovering residual drug and could spread the vesicant along the catheter tract [2][3]. |
| 4 | Give hyaluronidase and apply a warm compress as ordered | For vinca alkaloids such as vinblastine, hyaluronidase is the specific antidote. It degrades hyaluronic acid in the extracellular matrix, dispersing the drug and facilitating its absorption. Warm compresses promote vasodilation and further dispersion [1][3]. |
Watch out! Do not remove the catheter before aspirating. The catheter is the only conduit for recovering residual vesicant. Removing it first forfeits that opportunity and may drag the drug through healthy tissue.
Key point! The antidote and temperature modality are drug-specific. Vinca alkaloids (vinblastine, vincristine, vinorelbine) require hyaluronidase plus
warm compresses. In contrast, anthracyclines (e.g., doxorubicin) are managed with dexrazoxane and
cold compresses, and cold is also used for some other vesicants to limit cellular uptake
[1][3].
Why Hyaluronidase and Warm Compresses for Vinblastine
Vinblastine binds to tubulin and disrupts microtubule assembly, but its vesicant injury is driven largely by local tissue persistence and inflammation.
Hyaluronidase enzymatically breaks down hyaluronic acid, a major component of the interstitial matrix, creating channels that allow the leaked vinblastine to diffuse away from the injection site and be absorbed systemically. Warm compresses enhance this effect by increasing local blood flow and capillary permeability, which accelerates drug dispersion and reduces the concentration gradient at the injury site
[1][3].
This contrasts with anthracycline extravasation, where the drug binds to DNA in local cells and cold compresses are used to cause vasoconstriction, limiting further drug uptake and containing the injury. For vinca alkaloids, the goal is dispersion rather than containment, which is why warm—not cold—is indicated
[1][3].
Clinical Priority and Nursing Implications
The sequence reflects a hierarchy of harm reduction.
Stopping the infusion is the highest priority because every second of continued injection adds more vesicant to the tissue. Aspiration is second because it can actively remove drug, but only if the catheter is still in place. Catheter removal is third because it is necessary but should not precede attempts at drug recovery. Pharmacologic and physical interventions are last because they address the drug that could not be removed mechanically
[1][2][3].
Early detection is critical. The nurse must recognize burning, swelling, and absent blood return as cardinal signs of extravasation and act without delay. Delayed intervention increases the risk of progression to ulceration, necrosis, and potential need for surgical debridement
[1][3]. Documentation should include the time of onset, estimated volume extravasated, appearance of the site, interventions performed, and the prescriber notified.
References (research sources)
- [1]
ONS/ASCO Guideline on the Management of Antineoplastic Extravasation.GuidelineThomas T, Clark C, Backler C, Bohlke K, Centofanti D, Jotwani AC (2025) · DOI: 10.1188/25.CJON.384-399
- [2]
Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology.GuidelineMatsumoto K, Ryushima Y, Sato J, Aizawa Y, Aoyama T, Akaishi Y, Okamoto R, Sato Y, Sugano K, Tazumi K, Tsuji M, Fujikawa N, Bun S, Yagasaki K. (2024) · DOI: 10.1016/j.esmoop.2024.103932
- [3]
Chemotherapy extravasation: diagnosis, prevention and management.Research articleDuminuco A, Novello G, Mauro E, Scalisi E, Del Fabro V, Sambataro D (2026) · DOI: 10.1080/1120009X.2025.2488599